S01E30 | Inhaled GM-CSF for PAP — Is This the End of Whole-Lung Lavage?

In this episode of PRISM Rounds, we review the NEJM IMPALA-2 trial evaluating inhaled molgramostim for autoimmune pulmonary alveolar proteinosis (PAP).This phase 3 randomized trial showed improved pulmonary gas transfer (DLCO) and quality of life with inhaled GM-CSF compared to placebo, with a favorable safety profile. We break down the pathophysiology, trial design, and what this means for moving beyond whole-lung lavage in PAP.Article:https://pubmed.ncbi.nlm.nih.gov/40834301/Editorial:https://pubmed.ncbi.nlm.nih.gov/40834306/Tags:#CriticalCare #Pulmonary #ICU #FOAMed #MedEd #MedicalPodcast #PRISMRounds #NEJM #ClinicalTrials #EvidenceBasedMedicine #PAP #PulmonaryAlveolarProteinosis #GMCSF #Molgramostim #RareDisease #RespiratoryMedicine #ICUEducation #MedTwitter #HealthcareEducation #JournalClub